{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:09:10Z","timestamp":1784635750330,"version":"3.55.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Stafford Fox Medical Research Foundation"},{"DOI":"10.13039\/100008718","name":"Mason Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008718","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Compromised natural killer (NK) cell cytotoxic function is a well-documented and consistent feature of myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS). Other outcomes evaluated in NK cells of ME\/CFS patients, however, remain equivocal. The aim of this study was to conduct a systematic review of the literature regarding NK cell phenotype, receptor expression, cytokine production and cytotoxicity in ME\/CFS patients and determine the appropriateness as a model for ME\/CFS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Medline (EBSCOHost), Scopus, EMBASE and PubMed databases were systematically searched to source relevant papers published between 1994 and March 2018. This review included studies examining NK cells\u2019 features in ME\/CFS patients compared with HC following administration of specific inclusion and exclusion criteria. Secondary outcomes included genetic analysis in isolated NK cells or quality of life assessment. Quality assessment was completed using the Downs and Black checklist in addition to The Joanna Briggs Institute checklist.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventeen eligible publications were included in this review. All studies were observational case control studies. Of these, 11 investigated NK cell cytotoxicity, 14 investigated NK cell phenotype and receptor profiles, three examined NK cell cytokine production, six investigated NK cell lytic protein levels and four investigated NK cell degranulation. Impaired NK cell cytotoxicity remained the most consistent immunological report across all publications. Other outcomes investigated differed between studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A consistent finding among all papers included in this review was impaired NK cell cytotoxicity, suggesting that it is a reliable and appropriate cellular model for continued research in ME\/CFS patients. Aberrations in NK cell lytic protein levels were also reported. Although additional research is recommended, current research provides a foundation for subsequent investigations. It is possible that NK cell abnormalities can be used to characterise a subset of ME\/CFS due to the heterogeneity of both the illness itself and findings between studies investigating specific features of NK function.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13643-019-1202-6","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T14:03:10Z","timestamp":1573740190000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["A systematic review of natural killer cells profile and cytotoxic function in myalgic encephalomyelitis\/chronic fatigue syndrome"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0815-3162","authenticated-orcid":false,"given":"Natalie","family":"Eaton-Fitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"du Preez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Cabanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Staines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Marshall-Gradisnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,14]]},"reference":[{"key":"1202_CR1","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1128\/JCM.28.6.1403-1410.1990","volume":"28","author":"NG Klimas","year":"1990","unstructured":"Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol. 1990;28:1403\u201310.","journal-title":"J Clin Microbiol"},{"key":"1202_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1479-5876-9-81","volume":"9","author":"EW Brenu","year":"2011","unstructured":"Brenu EW, van Driel ML, Staines DR, Ashton KJ, Ramos SB, Keane J, et al. Immunological abnormalities as potential biomarkers in chronic fatigue syndrome\/myalgic encephalomyelitis. J Transl Med. 2011;9:81.","journal-title":"J Transl Med"},{"key":"1202_CR3","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/j.1365-2362.2010.02310.x","volume":"40","author":"KG Hollingsworth","year":"2010","unstructured":"Hollingsworth KG, Jones DE, Taylor R, Blamire AM, Newton JL. Impaired cardiovascular response to standing in chronic fatigue syndrome. Eur J Clin Investig. 2010;40:608\u201315.","journal-title":"Eur J Clin Investig"},{"key":"1202_CR4","first-page":"1","volume":"2","author":"S Myhill","year":"2009","unstructured":"Myhill S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med. 2009;2:1.","journal-title":"Int J Clin Exp Med"},{"key":"1202_CR5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/cei.12882","volume":"187","author":"T Nguyen","year":"2017","unstructured":"Nguyen T, Johnston S, Clarke L, Smith P, Staines D, Marshall-Gradisnik S. Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome\/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels. Clin Exp Immunol. 2017;187:284\u201393.","journal-title":"Clin Exp Immunol"},{"key":"1202_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CLEP.S39876","volume":"5","author":"S Johnston","year":"2013","unstructured":"Johnston S, Brenu EW, Staines D, Marshall-Gradisnik S. The prevalence of chronic fatigue syndrome\/myalgic encephalomyelitis: a meta-analysis. Clin Epidemiol. 2013;5:105.","journal-title":"Clin Epidemiol"},{"key":"1202_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1365-2796.2011.02428.x","volume":"270","author":"BM Carruthers","year":"2011","unstructured":"Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. Myalgic encephalomyelitis: international consensus criteria. J Intern Med. 2011;270:327\u201338.","journal-title":"J Intern Med"},{"key":"1202_CR8","doi-asserted-by":"publisher","first-page":"953","DOI":"10.7326\/0003-4819-121-12-199412150-00009","volume":"121","author":"K Fukuda","year":"1994","unstructured":"Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med. 1994;121:953\u20139.","journal-title":"Ann Intern Med"},{"key":"1202_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1300\/J092v11n01_02","volume":"11","author":"BM Carruthers","year":"2003","unstructured":"Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner AM, et al. Myalgic encephalomyelitis\/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. J Chronic Fatigue Syndr. 2003;11:7\u2013115.","journal-title":"J Chronic Fatigue Syndr"},{"key":"1202_CR10","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.bbi.2007.04.007","volume":"21","author":"M ter Wolbeek","year":"2007","unstructured":"ter Wolbeek M, van Doornen LJ, Kavelaars A, van de Putte EM, Schedlowski M, Heijnen CJ. Longitudinal analysis of pro-and anti-inflammatory cytokine production in severely fatigued adolescents. Brain Behav Immun. 2007;21:1063\u201374.","journal-title":"Brain Behav Immun"},{"key":"1202_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1365-2249.2004.02354.x","volume":"135","author":"A Skowera","year":"2004","unstructured":"Skowera A, Cleare A, Blair D, Bevis L, Wessely SC, Peakman M. High levels of type 2 cytokine-producing cells in chronic fatigue syndrome. Clin Exp Immunol. 2004;135:294\u2013302.","journal-title":"Clin Exp Immunol"},{"key":"1202_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1479-5876-7-96","volume":"7","author":"MA Fletcher","year":"2009","unstructured":"Fletcher MA, Zeng XR, Barnes Z, Levis S, Klimas NG. Plasma cytokines in women with chronic fatigue syndrome. J Transl Med. 2009;7:96.","journal-title":"J Transl Med"},{"key":"1202_CR13","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.bbi.2010.04.012","volume":"24","author":"G Broderick","year":"2010","unstructured":"Broderick G, Fuite J, Kreitz A, Vernon SD, Klimas N, Fletcher MA. A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun. 2010;24:1209\u201317.","journal-title":"Brain Behav Immun"},{"key":"1202_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s13317-013-0051-x","volume":"4","author":"EW Brenu","year":"2013","unstructured":"Brenu EW, Hardcastle SL, Atkinson GM, van Driel ML, Kreijkamp-Kaspers S, Ashton KJ, et al. Natural killer cells in patients with severe chronic fatigue syndrome. Autoimmun Highlights. 2013;4:69\u201380.","journal-title":"Autoimmun Highlights"},{"key":"1202_CR15","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.4049\/jimmunol.139.10.3306","volume":"139","author":"M Caligiuri","year":"1987","unstructured":"Caligiuri M, Murray C, Buchwald D, Levine H, Cheney P, Peterson D, et al. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol. 1987;139:3306\u201313.","journal-title":"J Immunol"},{"key":"1202_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/sji.12388","volume":"83","author":"TK Huth","year":"2016","unstructured":"Huth TK, Brenu EW, Ramos S, Nguyen T, Broadley S, Staines D, et al. Pilot study of natural killer cells in chronic fatigue syndrome\/myalgic encephalomyelitis and multiple sclerosis. Scand J Immunol. 2016;83:44\u201351.","journal-title":"Scand J Immunol"},{"key":"1202_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12865-015-0101-4","volume":"16","author":"SL Hardcastle","year":"2015","unstructured":"Hardcastle SL, Brenu EW, Johnston S, Nguyen T, Huth T, Wong N, et al. Characterisation of cell functions and receptors in chronic fatigue Syndrome\/Myalgic encephalomyelitis (CFS\/ME). BMC Immunol. 2015;16:35.","journal-title":"BMC Immunol"},{"key":"1202_CR18","doi-asserted-by":"crossref","unstructured":"Masuda A, Nozoe S-I, Matsuyama T, Tanaka H. Psychobehavioral and immunological characteristics of adult people with chronic fatigue and patients with chronic fatigue syndrome. Psychosom Med. 1994;","DOI":"10.1097\/00006842-199411000-00006"},{"key":"1202_CR19","doi-asserted-by":"publisher","first-page":"27S","DOI":"10.1016\/S0002-9343(98)00155-7","volume":"105","author":"TL Whiteside","year":"1998","unstructured":"Whiteside TL, Friberg D. Natural killer cells and natural killer cell activity in chronic fatigue syndrome. Am J Med. 1998;105:27S\u201334S.","journal-title":"Am J Med"},{"key":"1202_CR20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1365-2249.2005.02935.x","volume":"142","author":"KJ Maher","year":"2005","unstructured":"Maher KJ, Klimas NG, Fletcher MA. Chronic fatigue syndrome is associated with diminished intracellular perforin. Clin Exp Immunol. 2005;142:505\u201311.","journal-title":"Clin Exp Immunol"},{"key":"1202_CR21","first-page":"2","volume":"5","author":"T Huth","year":"2014","unstructured":"Huth T, Brenu E, Nguyen T, Hardcastle S, Johnston S, Ramos S. Characterization of natural killer cell phenotypes in chronic fatigue syndrome\/myalgic encephalomyelitis. J Clin Cell Immunol. 2014;5:2.","journal-title":"J Clin Cell Immunol"},{"key":"1202_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40360-018-0203-8","volume":"19","author":"N Eaton","year":"2018","unstructured":"Eaton N, Cabanas H, Balinas C, Klein A, Staines D, Marshall-Gradisnik S. Rituximab impedes natural killer cell function in chronic fatigue Syndrome\/Myalgic encephalomyelitis patients: a pilot in vitro investigation. BMC Pharmacol Toxicol. 2018;19:12.","journal-title":"BMC Pharmacol Toxicol"},{"key":"1202_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12967-016-0859-z","volume":"14","author":"TK Huth","year":"2016","unstructured":"Huth TK, Staines D, Marshall-Gradisnik S. ERK1\/2, MEK1\/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim\/\u2212 natural killer cells in chronic fatigue Syndrome\/Myalgic encephalomyelitis patients. J Transl Med. 2016;14:97.","journal-title":"J Transl Med"},{"key":"1202_CR24","first-page":"2","volume":"5","author":"SL Hardcastle","year":"2014","unstructured":"Hardcastle SL, Brenu E, Johnston S, Nguyen T, Huth T, Kaur M. Analysis of the relationship between immune dysfunction and symptom severity in patients with chronic fatigue syndrome\/myalgic encephalomyelitis (CFS\/ME). J Clin Cell Immunol. 2014;5:2.","journal-title":"J Clin Cell Immunol"},{"key":"1202_CR25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/intimm\/dxt068","volume":"26","author":"EW Brenu","year":"2013","unstructured":"Brenu EW, Huth TK, Hardcastle SL, Fuller K, Kaur M, Johnston S, et al. Role of adaptive and innate immune cells in chronic fatigue syndrome\/myalgic encephalomyelitis. Int Immunol. 2013;26:233\u201342.","journal-title":"Int Immunol"},{"key":"1202_CR26","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1046\/j.1365-2362.1998.00373.x","volume":"28","author":"M Ogawa","year":"1998","unstructured":"Ogawa M, Nishiura T, Yoshimura M, Horikawa Y, Yoshida H, Okajima Y, et al. Decreased nitric oxide-mediated natural killer cell activation in chronic fatigue syndrome. Eur J Clin Investig. 1998;28:937\u201343.","journal-title":"Eur J Clin Investig"},{"key":"1202_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1006\/clin.1998.4554","volume":"88","author":"PH Levine","year":"1998","unstructured":"Levine PH, Whiteside TL, Friberg D, Bryant J, Colclough G, Herberman RB. Dysfunction of natural killer activity in a family with chronic fatigue syndrome. Clin Immunol Immunopathol. 1998;88:96\u2013104.","journal-title":"Clin Immunol Immunopathol"},{"key":"1202_CR28","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.1093\/clinids\/18.Supplement_1.S157","volume":"18","author":"EA Ojo-Amaize","year":"1994","unstructured":"Ojo-Amaize EA, Conley EJ, Peter JB. Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome. Clin Infect Dis. 1994;18:S157\u20139.","journal-title":"Clin Infect Dis"},{"key":"1202_CR29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","volume":"9","author":"E Vivier","year":"2008","unstructured":"Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9:503.","journal-title":"Nat Immunol"},{"key":"1202_CR30","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","volume":"126","author":"A Poli","year":"2009","unstructured":"Poli A, Michel T, Th\u00e9r\u00e9sine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126:458\u201365.","journal-title":"Immunology"},{"key":"1202_CR31","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","volume":"22","author":"MA Cooper","year":"2001","unstructured":"Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633\u201340.","journal-title":"Trends Immunol"},{"key":"1202_CR32","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","volume":"112","author":"MA Caligiuri","year":"2008","unstructured":"Caligiuri MA. Human natural killer cells. Blood. 2008;112:461\u20139.","journal-title":"Blood"},{"key":"1202_CR33","first-page":"1603","volume":"2013","author":"EC Schwarz","year":"1833","unstructured":"Schwarz EC, Qu B, Hoth M. Calcium, cancer and killing: the role of calcium in killing cancer cells by cytotoxic T lymphocytes and natural killer cells. Biochim Biophys Acta BBA-Mol Cell Res. 1833;2013:1603\u201311.","journal-title":"Biochim Biophys Acta BBA-Mol Cell Res"},{"key":"1202_CR34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ni1581","volume":"9","author":"LL Lanier","year":"2008","unstructured":"Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9:495.","journal-title":"Nat Immunol"},{"key":"1202_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jim.2004.08.008","volume":"294","author":"G Alter","year":"2004","unstructured":"Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294:15\u201322.","journal-title":"J Immunol Methods"},{"key":"1202_CR36","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nri911","volume":"2","author":"JA Trapani","year":"2002","unstructured":"Trapani JA, Smyth MJ. Functional significance of the perforin\/granzyme cell death pathway. Nat Rev Immunol. 2002;2:735.","journal-title":"Nat Rev Immunol"},{"key":"1202_CR37","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/0167-5699(95)80122-7","volume":"16","author":"MJ Smyth","year":"1995","unstructured":"Smyth MJ, Trapani JA. Granzymes: exogenous porteinases that induce target cell apoptosis. Immunol Today. 1995;16:202\u20136.","journal-title":"Immunol Today"},{"key":"1202_CR38","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1074\/jbc.M806716200","volume":"284","author":"N Bovenschen","year":"2009","unstructured":"Bovenschen N, Quadir R, van den Berg AL, Brenkman AB, Vandenberghe I, Devreese B, et al. Granzyme K displays highly restricted substrate specificity that only partially overlaps with granzyme a. J Biol Chem. 2009;284:3504\u201312.","journal-title":"J Biol Chem"},{"key":"1202_CR39","unstructured":"Martin J. \u00a9 Joanna Briggs Institute 2017 Critical Appraisal Checklist for Case Series. 2017:7."},{"key":"1202_CR40","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jech.52.6.377","volume":"52","author":"SH Downs","year":"1998","unstructured":"Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52:377\u201384.","journal-title":"J Epidemiol Community Health"},{"key":"1202_CR41","doi-asserted-by":"crossref","unstructured":"Hooper P, Jutai JW, Strong G, Russell-Minda E. Age-related macular degeneration and low-vision rehabilitation: a systematic review: Centre for Reviews and Dissemination (UK); 2008.","DOI":"10.3129\/i08-001"},{"key":"1202_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-8-1","volume":"8","author":"EW Brenu","year":"2010","unstructured":"Brenu EW, Staines DR, Baskurt OK, Ashton KJ, Ramos SB, Christy RM, et al. Immune and hemorheological changes in chronic fatigue syndrome. J Transl Med. 2010;8:1. https:\/\/doi.org\/10.1186\/1479-5876-8-1.","journal-title":"J Transl Med"},{"key":"1202_CR43","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1479-5876-10-88","volume":"10","author":"EW Brenu","year":"2012","unstructured":"Brenu EW, van Driel ML, Staines DR, Ashton KJ, Hardcastle SL, Keane J, et al. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome\/myalgic encephalomyelitis. J Transl Med. 2012;10:88. https:\/\/doi.org\/10.1186\/1479-5876-10-88.","journal-title":"J Transl Med"},{"key":"1202_CR44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/TACG.S99405","volume":"9","author":"S Marshall-Gradisnik","year":"2016","unstructured":"Marshall-Gradisnik S, Huth T, Chacko A, Johnston S, Smith P, Staines D. Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis\/chronic fatigue syndrome. Appl Clin Genet. 2016;9:39.","journal-title":"Appl Clin Genet"},{"key":"1202_CR45","doi-asserted-by":"publisher","first-page":"e10817","DOI":"10.1371\/journal.pone.0010817","volume":"5","author":"MA Fletcher","year":"2010","unstructured":"Fletcher MA, Zeng XR, Maher K, Levis S, Hurwitz B, Antoni M, et al. Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV\/CD26. PLoS One. 2010;5:e10817. https:\/\/doi.org\/10.1371\/journal.pone.0010817.","journal-title":"PLoS One"},{"key":"1202_CR46","doi-asserted-by":"publisher","unstructured":"Hardcastle SL, Brenu EW, Johnston S, Nguyen T, Huth T, Ramos S, et al. Longitudinal analysis of immune abnormalities in varying severities of chronic fatigue Syndrome\/Myalgic encephalomyelitis patients. J Transl Med. 2015;13 https:\/\/doi.org\/10.1186\/s12967-015-0653-3.","DOI":"10.1186\/s12967-015-0653-3"},{"key":"1202_CR47","doi-asserted-by":"publisher","unstructured":"Theorell J, Bileviciute-Ljungar I, Tesi B, Schlums H, Johnsgaard MS, Asadi-Azarbaijani B, et al. Unperturbed cytotoxic lymphocyte phenotype and function in myalgic encephalomyelitis\/chronic fatigue syndrome patients. Front Immunol. 2017:8. https:\/\/doi.org\/10.3389\/fimmu.2017.00723.","DOI":"10.3389\/fimmu.2017.00723"},{"key":"1202_CR48","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/1479-5876-11-68","volume":"11","author":"M Curriu","year":"2013","unstructured":"Curriu M, Carrillo J, Massanella M, Rigau J, Alegre J, Puig J, et al. Screening NK-, B- and T-cell phenotype and function in patients suffering from chronic fatigue syndrome. J Transl Med. 2013;11:68. https:\/\/doi.org\/10.1186\/1479-5876-11-68.","journal-title":"J Transl Med"},{"key":"1202_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40659-016-0087-2","volume":"49","author":"T Nguyen","year":"2016","unstructured":"Nguyen T, Staines D, Nilius B, Smith P, Marshall-Gradisnik S. Novel identification and characterisation of transient receptor potential melastatin 3 ion channels on natural killer cells and B lymphocytes: effects on cell signalling in chronic fatigue syndrome\/Myalgic encephalomyelitis patients. Biol Res. 2016;49:27.","journal-title":"Biol Res"},{"key":"1202_CR50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/cyto.b.10034","volume":"53","author":"CC Stewart","year":"2003","unstructured":"Stewart CC, Cookfair DL, Hovey KM, Wende KE, Bell DS, Warner CL. Predictive immunophenotypes: disease-related profile in chronic fatigue syndrome. Cytometry B Clin Cytom. 2003;53:26\u201333. https:\/\/doi.org\/10.1002\/cyto.b.10034.","journal-title":"Cytometry B Clin Cytom"},{"key":"1202_CR51","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3389\/fimmu.2018.01028","volume":"9","author":"JL Rivas","year":"2018","unstructured":"Rivas JL, Palencia T, Fern\u00e1ndez G, Garc\u00eda M. Association of T and nK cell phenotype with the diagnosis of myalgic encephalomyelitis\/chronic fatigue syndrome (Me\/cFs). Front Immunol. 2018;9:1028.","journal-title":"Front Immunol"},{"key":"1202_CR52","doi-asserted-by":"crossref","unstructured":"Longitudinal associations of lymphocyte subsets with clinical outcomes in chronic fatigue syndrome: Fatigue. 6, 2 n.d. https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/21641846.2018.1426371 (Accessed 24 Aug 2018).","DOI":"10.1080\/21641846.2018.1426371"},{"key":"1202_CR53","unstructured":"Syndrome C on the DC for MEF, Populations B on the H of S, Medicine I of. Current Case Definitions and Diagnostic Criteria, Terminology, and Symptom Constructs and Clusters. National Academies Press (US); 2015."},{"key":"1202_CR54","doi-asserted-by":"crossref","unstructured":"Case definitions for chronic fatigue syndrome\/myalgic encephalomyelitis (CFS\/ME): a systematic review. BMJ Open n.d. https:\/\/bmjopen.bmj.com\/content\/4\/2\/e003973 (Accessed 9 Dec 2018).","DOI":"10.1136\/bmjopen-2013-003973"},{"key":"1202_CR55","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/(SICI)1097-0320(19991101)37:3<197::AID-CYTO6>3.0.CO;2-L","volume":"37","author":"JP Aubry","year":"1999","unstructured":"Aubry JP, Blaecke A, Lecoanet-Henchoz S, Jeannin P, Herbault N, Caron G, et al. Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. Cytometry. 1999;37:197\u2013204.","journal-title":"Cytometry"},{"key":"1202_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0022-1759(94)00293-6","volume":"180","author":"D Flieger","year":"1995","unstructured":"Flieger D, Gruber R, Schlimok G, Reiter C, Pantel K, Riethm\u00fcller G. A novel non-radioactive cellular cytotoxicity test based on the differential assessment of living and killed target and effector cells. J Immunol Methods. 1995;180:1\u201313.","journal-title":"J Immunol Methods"},{"key":"1202_CR57","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/rheumatology\/keg240","volume":"42","author":"C Pridgeon","year":"2003","unstructured":"Pridgeon C, Lennon GP, Pazmany L, Thompson RN, Christmas SE, Moots RJ. Natural killer cells in the synovial fluid of rheumatoid arthritis patients exhibit a CD56bright,CD94bright,CD158negative phenotype. Rheumatol Oxf Engl. 2003;42:870\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/keg240.","journal-title":"Rheumatol Oxf Engl"},{"key":"1202_CR58","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1084\/jem.188.5.953","volume":"188","author":"A Pessino","year":"1998","unstructured":"Pessino A, Sivori S, Bottino C, Malaspina A, Morelli L, Moretta L, et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med. 1998;188:953\u201360. https:\/\/doi.org\/10.1084\/jem.188.5.953.","journal-title":"J Exp Med"},{"key":"1202_CR59","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1017\/S0958067000020972","volume":"85","author":"MF van den Broek","year":"2000","unstructured":"van den Broek MF, Hengartner H. The role of perforin in infections and tumour surveillance. Exp Physiol. 2000;85:681\u20135.","journal-title":"Exp Physiol"},{"key":"1202_CR60","doi-asserted-by":"publisher","first-page":"109","DOI":"10.5114\/ceji.2014.42135","volume":"39","author":"I Osi\u0144ska","year":"2014","unstructured":"Osi\u0144ska I, Popko K, Demkow U. Perforin: an important player in immune response. Cent-Eur J Immunol. 2014;39:109\u201315. https:\/\/doi.org\/10.5114\/ceji.2014.42135.","journal-title":"Cent-Eur J Immunol"},{"key":"1202_CR61","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.bbapap.2005.08.017","volume":"1754","author":"B Kaminska","year":"2005","unstructured":"Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy\u2014from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta. 2005;1754:253\u201362. https:\/\/doi.org\/10.1016\/j.bbapap.2005.08.017.","journal-title":"Biochim Biophys Acta"},{"key":"1202_CR62","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1158\/1535-7163.MCT-12-0692","volume":"11","author":"MK Gleason","year":"2012","unstructured":"Gleason MK, Verneris MR, Todhunter DA, Zhang B, McCullar V, Zhou SX, et al. Bispecific and Trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther. 2012;11:2674\u201384. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-0692.","journal-title":"Mol Cancer Ther"},{"key":"1202_CR63","doi-asserted-by":"crossref","unstructured":"Calcium-dependent plasma membrane binding and cell lysis by perforin are mediated through its C2 domain n.d. http:\/\/www.jbc.org\/content\/280\/9\/8426.full.html (Accessed 26 July 2018).","DOI":"10.1074\/jbc.M413303200"},{"key":"1202_CR64","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s10020-018-0046-1","volume":"24","author":"H Cabanas","year":"2018","unstructured":"Cabanas H, Muraki K, Eaton N, Balinas C, Staines D, Marshall-Gradisnik S. Loss of transient receptor potential Melastatin 3 ion channel function in natural killer cells from chronic fatigue Syndrome\/Myalgic encephalomyelitis patients. Mol Med. 2018;24:44. https:\/\/doi.org\/10.1186\/s10020-018-0046-1.","journal-title":"Mol Med"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-019-1202-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13643-019-1202-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-019-1202-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T23:02:58Z","timestamp":1695423778000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-019-1202-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,14]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1202"],"URL":"https:\/\/doi.org\/10.1186\/s13643-019-1202-6","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,14]]},"assertion":[{"value":"17 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Consent for publication was obtained from all persons involved in the writing and planning of this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest. The lead author affirms that this manuscript is an accurate, honest and transparent account of the study undertaken and reported, with no aspects being omitted and any discrepancies explained. The reporting of this work is compliant with PRISMA guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"279"}}